NCT05665985 is a Phase 1, PHASE2 clinical trial of Moringa Oleifera in Rheumatoid Arthritis, sponsored by Universitas Sebelas Maret.

Who is sponsoring NCT05665985?

NCT05665985 is sponsored by Universitas Sebelas Maret.

What drugs are being tested in NCT05665985?

Interventions in NCT05665985: Moringa Oleifera.

What condition does NCT05665985 study?

NCT05665985 studies Rheumatoid Arthritis.

Is NCT05665985 still recruiting?

NCT05665985 is currently completed. Last updated 27 December 2022.

Last reviewed 2022-12-27 · How we verify

NCT05665985

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect Of Moringa Leaf Extract On Disease Activity In Rheumatoid Arthritis Patients

Completed Phase 1, PHASE2 Last updated 27 December 2022

What this trial tests

Phase 1, PHASE2 trial testing Moringa Oleifera in Rheumatoid Arthritis in 30 participants. Completed in 30 September 2020.

Timeline

1 May 2020

Primary endpoint
30 July 2020

30 September 2020

Quick facts

Lead sponsor	Universitas Sebelas Maret
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	30
Start date	1 May 2020
Primary completion	30 July 2020
Estimated completion	30 September 2020
Sites	1 location across Indonesia

Drugs / interventions tested

Moringa Oleifera — full drug profile →

Conditions studied

Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →

Sponsor

Universitas Sebelas Maret — full company profile →

Who can join

Adults 18 to 60, female only, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intervention therapy study of moringa oliefera extract on the degree of activity of rheumatoid arthritis patients. The research subjects were patients with rheumatoid arthritis-intervention with moringa oliefera for 30 days.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Harnessing Nature's Toolbox: Naturally Derived Bioactive Compounds in Nanotechnology Enhanced Formulations.
Sanjai C, Gaonkar SL, Hakkimane SS. · · 2024 · cited 10× · PMID 39494011 · DOI 10.1021/acsomega.4c07756
The "Colors" of Moringa: Biotechnological Approaches.
Villegas-Vazquez EY, Padilla-Mendoza JR, Carrillo-Pérez MS, Gómez-Cansino R, et al · · 2025 · PMID 40805688 · DOI 10.3390/plants14152338

Verify or expand the search:

Other trials of Moringa Oleifera

Trials testing the same drug.

NCT06905379 — Remineralization Efficacy of Moringa Oleifera Varnish Vs MI Varnish in Initial Carious Lesions Over 6 Months Follow Up: · NA · not yet recruiting
NCT07037498 — Effect of Moringa Royal Jelly on the Nutritional Status and Cognitive Level of Adolescent Girls · NA · active not recruiting

Other recruiting trials for Rheumatoid Arthritis

Currently open trials in the same condition.

NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting

Other Universitas Sebelas Maret trials

Trials by the same sponsor.

NCT07475065 — The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy · Phase 2, PHASE3 · not yet recruiting
NCT07039682 — Empowering Knowledge, Self-Testing & Resilience Through Innovative Methods for HIV · NA · not yet recruiting
NCT07380178 — The Effect of Apple Fruit Extract (Malus Sylvestris Mill) as an Antioxidant and Anti-Inflammatory on Allergic Rhinitis · NA · completed
NCT06871358 — The Effect of Atorvastatin 80 mg on Hs-CRP/Albumin Ratio in Reducing Thrombus Burden in PCI-STEMI Patients · NA · completed
NCT07121569 — Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and Outcomes · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05665985 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitas Sebelas Maret
Last refreshed: 27 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05665985.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing